Tavares, IsabelSilvano, JoséMoreira, LucianaOliveira, Márcia E.Silva, RobertoSampaio, SusanaCosta, Paulo PinhoLobato, Luísa2020-05-072020-05-072019-07-25Amyloid. 2019;26(Supl1):162-163. doi: 10.1080/13506129.2019.1583196. Epub 2019 Jul 251350-6129http://hdl.handle.net/10400.18/6608Introduction: Fibrinogen Aa chain (AFib) amyloidosis is an autosomal dominant disease that typically presents with predominant renal involvement and has a predictable progressive clinical course [1]. The p.Glu545Val AFib gene (FGA) mutation is at the origin of all AFib amyloidosis cases (AFibE526V [p.Glu545Val]) that have been identified in Portugal so far, and accounts for the disease in 17 families. Current treatment of AFib amyloidosis comprises both supportive measures and disease-modifying approaches, such as liver transplantation [2,3]. Renal transplantation (RTx) is a supportive therapy with risk of premature graft loss due to amyloid recurrence or other unexpected complications related to progression of extrarenal amyloid deposition. The aim of this study was to evaluate the outcome of Portuguese patients with AFibE526V (p.Glu545Val) amyloidosis after RTx.engAdultAgedAmino Acid SubstitutionFemaleHumansMaleMiddle AgedAmyloidosisFibrinogenGraft RejectionKidney TransplantationMutation, MissenseDoenças Genéticasjournal article10.1080/13506129.2019.1583196